The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The Bruton’s tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with relapsed and refractory non-GCB-DLBCL.
Martin Dyer
Honoraria - Ono Pharmaceutical
Research Funding - Ono Pharmaceutical
Claire Hutchinson
Research Funding - Ono Pharmaceutical
Simon Rule
No relevant relationships to disclose
Nimish Shah
No relevant relationships to disclose
Gilles A. Salles
Honoraria - Celgene; Gilead Sciences; Janssen
Lionel Karlin
Honoraria - Celgene; Janssen
Franck Morschhauser
Honoraria - Celgene; Mundipharma; Ono Pharmaceutical ; Roche
Louis Terriou
No relevant relationships to disclose
Christopher Fegan
Honoraria - Ono Pharmaceutical
Andrew Davison
No relevant relationships to disclose
Guillaume Cartron
Honoraria - Ono Pharmaceutical
Andrew Saunders
Consultant or Advisory Role - Ono Pharmaceutical ; Pharmacyclics
Hideyuki Honda
Employment or Leadership Position - Ono Pharmaceutical
John Sharpe
Employment or Leadership Position - Ono Pharmaceutical
Toshio Yoshizawa
Employment or Leadership Position - Ono Pharmaceutical
Tomoko Yasuhiro
Employment or Leadership Position - Ono Pharmaceutical
Kazuhito Kawabata
Employment or Leadership Position - Ono Pharmaceutical
Hiroshi Awata
Employment or Leadership Position - Ono Pharmaceutical
Joseph Birkett
Employment or Leadership Position - Ono Pharmaceutical